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ABSTRACT  22 
Xeno-estrogens, a class of endocrine disrupting chemicals (EDCs), can disturb 23 
estrogen receptor-dependent pathways involved in differentiation, proliferation or protection. 24 
Multiple methods have been developed to characterize the disturbances induced by EDCs in 25 
different cells or organs. In this study we have developed a new tool for the assessment of 26 
estrogenic compounds on differentiation. For this purpose we used the global model of NGF-27 
induced neurite outgrowth of a pseudoneuronal PC12 cell line stably transfected with estrogen 28 
receptor alpha (PC12 ER). This new test evidences a new selectivity in which estradiol, 29 
genistein and 4-hydroxytamoxifen increased the NGF-induced neurite outgrowth of PC12 ER 30 
cells in a dose-dependent manner. In contrast, the strong estrogen agonist 17-31 
ethynylestradiol, the strong antagonist raloxifene and the agonist bisphenol A were unable to 32 
modify the neuritogenesis of PC12 ER cells. Therefore, the analysis of neuritogenesis in 33 
PC12 ER cells constitutes a complementary tool for the characterization of xeno-estrogen 34 
activity and also serves as a basis for further studies focusing on the mechanisms of EDCs in 35 
a neuronal context. Moreover, this test constitutes an alternative to animal testing. 36 
 37 
Key Words: Estrogen, endocrine-disrupting chemicals, PC12 cells, estrogen receptor, 38 
differentiation. 39 
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1. INTRODUCTION 40 
 41 
It is known that estradiol (E2) acts on the reproductive system. However, it also has numerous 42 
actions on non-reproductive tissues such as bone, the cardiovascular system, the brain and the 43 
immune system (Turgeon et al., 2006). Several studies have reported that the actions of 44 
endogenous estrogens could be disrupted by pollutants, particularly xeno-estrogens, a family 45 
among endocrine-disrupting chemicals (EDCs) (Colborn et al., 1993; Guillette et al., 1994; 46 
Toppari et al., 1996). The primary environmental problem is that EDCs are widely dispersed 47 
in surface water (Campbell et al., 2006) throughout the world and the detected concentrations 48 
are mainly linked to waste water treatment plan that is not efficient enough to remove the 49 
overall compounds (Hamid and Eskicioglu, 2012). Their presence in environment constitutes 50 
a risk for Human and wildlife. In this context, the European Parliament has recently voted the 51 
inclusion in the list of priority substances of the Water Framework Directive, two well-known 52 
estrogenic compounds: E2 and 17-ethynylestradiol (EE2), being used as pharmaceuticals 53 
(European Parliament News, 2012). These two compounds are present in environment at ng/L 54 
and ng/g in river and sediment (Huang et al., 2013; Leusch et al., 2013; Esteban et al., 2014). 55 
Therefore, several in vivo and in vitro methods have been developed to characterize the 56 
response of E2 as well as of other EDCs (Andersen et al., 1999; Kerdivel et al., 2013). In vivo 57 
methods utilize different species to study the different physiological functions of estrogens. 58 
For example, uterotrophic growth has been studied in rodents (Odum et al., 1997), 59 
vitellogenin expression has been investigated in rainbow trouthepatocytes (Flouriot et al., 60 
1995; Sumpter and Jobling, 1995) or modification of life cycle was assessed in zebrafish 61 
(Micael et al., 2007). In vitro approaches were used to investigate the subcellular effects of E2 62 
and EDCs that are mediated by estrogen receptor (ER)-dependent mechanisms, particularly 63 
transcriptional or membrane-initiated mechanisms (Mendelsohn, 2000; Edwards, 2005). 64 
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Transcriptional studies primarily utilize in vitro short-term assays with reporter genes under 65 
the control of consensus sequences in their promoters, such as the estrogen response element 66 
(ERE)(Petit et al., 1995; Arnold et al., 1996; Andersen et al., 1999; Balaguer et al., 1999), the 67 
AP1- or SP1-binding sites(Fujimoto et al., 2004; Schreihofer, 2005). In parallel, other in vitro 68 
approaches were used to study the global cellular effects of EDCs. For instance, using the E-69 
Screen assay, studies report the proliferative effects of EDCs on ER positive breast cancer 70 
cells (Soto et al., 1992; Villalobos et al., 1995; Andersen et al., 1999). If xeno-estrogens have 71 
strong proliferative effects, they may also induce differentiating effects on certain tissues such 72 
as uterus, blood vessels, heart, bone and brain (Turgeon et al., 2006). With regard to the brain, 73 
many in vivo and in vitro studies have reported a role for E2 in brain protection and 74 
functioning (for review see Habauzit et al. 2011); however, there is no test currently available 75 
to assess the differentiating effects of EDCs in a neuronal context alternative to animal model.  76 
The PC12 cell line is derived from rat pheochromocytoma, a tumor arising from the 77 
adrenal medulla(Greene and Tischler, 1976) and is highly regarded among the in vitro 78 
neuronal cell models. Thus many studies have investigated the mechanisms of 79 
neurodegeneration/neuroprotection, in relation notably with Parkinson’s disease, by 80 
determination in PC12 cells of the biosynthesis and release of catecholamine (Kumar et al., 81 
1998; Yoneda et al., 2003; Ando et al., 2013), the modulation of redox activity (Shearman et 82 
al., 1994; Vimard et al., 2011). Other studies have investigated the mechanisms of 83 
differentiation, using the capacity to extend neurites when treated with nerve growth factor 84 
NGF (Gollapudi and Oblinger, 2001). Moreover the ability of PC12 cells to take into account 85 
the dependence on the ER status has also been reported: we previously demonstrated that the 86 
stable transfection of PC12 cells with ERα was able to modify differentiation (neurite 87 
outgrowth) or survival in the presence or not of the natural hormone E2 (Merot et al., 2005; 88 
Merot et al., 2009; Ferriere et al., 2013). 89 
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In this study, our objective was to develop a new tool for the evaluation of the EDC 90 
differentiating effect. In this way the EDC effect was evaluate in the context of 91 
undifferentiated / differentiated PC12 cells mainly by the evaluation of their ability to act on 92 
the classical estrogenic targets: transcription and differentiation. We used the following 93 
pharmaceutical products: 17-ethynylestradiol (EE2), which is widely used for birth control 94 
(Lobo and Stanczyk, 1994); raloxifene (Ral) and 4-hydroxytamoxifen (4-OHT), which are 95 
two selective estrogen receptor modulators (SERMS) that display varying degrees of agonist 96 
or antagonist activities depending on the cellular context (Ho and Liao, 2002); the industrial 97 
product bisphenol A (BPA), which is a plasticizer and one of the most common EDCs 98 
(Willhite et al., 2008) and the clinically relevant phytoestrogen genistein (Gen), which is a 99 
plant-derived isoflavone (Polkowski and Mazurek, 2000). The concentrations of compounds 100 
used in this study were previously demonstrated to be near the physiologically active 101 
concentrations and near the concentration levels found in environment and/or plasma 102 
(Habauzit et al., 2011; Waye and Trudeau, 2011). Here, we report that the determination of 103 
neuritogenesis in PC12 ER positive cells constitutes a new tool for screening purposes as this 104 
technique provides information that are complimentary to other global bioassays based on 105 
cellular proliferation or to short-term subcellular analysis. The determination of 106 
neuritogenesis could also be a basis for further studies focusing on the mechanisms of EDCs 107 
in a neuronal context, which is currently poorly documented.  108 
 109 
2. MATERIALS AND METHODS 110 
 111 
2.1. Materials 112 
The following reagents were purchased as powder from Sigma Aldrich (St. Louis, 113 
MO): E2, EE2, Gen, 4-OHT, Ral, BPA that were solubilized in ethanol or DMSO and then 114 
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prepared by serial dilutions. No differences were observed between EtOH and DMSO on 115 
nerve growth factor (NGF) induced PC12differentiation (data not shown). The final vehicle 116 
concentration was 0.1% in the culture medium. Recombinant NGF was prepared according 117 
supplier information (Sigma Aldrich, St. Louis, MO). The antibody raised against ERα C-118 
terminal (HC-20) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The 119 
antibody raised against β-actin (AC-15) was purchased from Sigma Aldrich (St. Louis, MO).  120 
 121 
2.2. Plasmids 122 
The ERα cDNA, ERE-TK-Luc and CMV-β-Gal reporter plasmids were previously 123 
described (Flouriot et al., 2000; Metivier et al., 2002). The SP1 reporter plasmids were 124 
obtained from Panomics (Panomics Inc., Fremont, CA). 125 
 126 
2.3. Transcriptional activity of ERα in undifferentiated and differentiated PC12 cells 127 
PC12 control and PC12 ER cells are naive PC12 cell lines that were transiently 128 
transfected respectively with the empty vector named pCR3.1 or with thepCR3.1 plasmid in 129 
which is integrated the coding sequence for full length Estrogen Receptor alpha (pCR3.1 130 
ERα). These transient plasmid transfections were used in order to distinguish the ER 131 
dependent from ER independent EDCs transcriptional activities. These transcriptional 132 
activities were determined on two ER transcriptional pathways: - an ER direct interaction 133 
with DNA through ER/estrogen response element interaction (ERE consensus sequence 134 
integrated in plasmid containing luciferase as indicator of the compounds effects, ERE-TK-135 
Luc) – an ER indirect interaction through the ER/specific factor 1 that binds with the SP1 136 
consensus DNA sequence (SP1 consensus sequence integrated in plasmid containing 137 
luciferase as indicator of the compounds effects, SP1-Luc). The plasmid CMV-β-gal was used 138 
for the normalization of the efficiency of the transient transfection, and the cytomegalovirus 139 
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promoter led the compound independent expression of the β-galactosidase enzyme. Briefly, 140 
transient transfections of wild-type PC12 cells were performed in 24-well plates using the 141 
JetPEI transfection reagent (Polyplus transfection, Saint Quentin Yvelines France). One hour 142 
prior to transfection, the standard culture medium was replaced with phenol red-free DMEM-143 
F12 containing 2% charcoal-stripped serum composed by 1.6% charcoal-stripped fetal calf 144 
serum and 0.4% charcoal-stripped horse serum. The cells were then transfected for 12 hours 145 
with a DNA mixture containing the expression vectors (100 ng per well) ERE-TK-Luc or 146 
SP1-Luc together with CMV-β-Gal as the internal control (100 ng per well) and either the 147 
expression vector pCR3.1 or pCR3.1 ERα (50 ng per well). The total plasmid amount was 148 
250 ng/well. After washing with PBS, different estrogenic compounds and/or Nerve growth 149 
factor (NGF; that initiates the PC12 cells neurite outgrowth) were added to the cells for 30 150 
hours in DMEM-F12 containing 2 % charcoal-stripped serum containing both fetal calf and 151 
horse serum. Cells were lysed with luciferase assay system with reporter lysis buffer 152 
(Promega, Madison). The reporter gene activity was quantified from the luciferase activity 153 
with Veritas Luminometer (Turner biosystems) and then the absorbance of the β-154 
galactosidase activity was determined with iMark microplate reader (Biorad). The luciferase 155 
activity was then normalized by β-galactosidase activity. The fold of induction was finally 156 
determined by the normalization of tested compound on the PC12 control (+/- ER) with 157 
ethanol alone or with ethanol and NGF co-treatment, considered as reference compound 158 
(Flouriot et al., 2000). 159 
 160 
2.4. Generation of stable PC12 ERα clones 161 
Stable PC12 clones (PC12 control and PC12 ER) were previously obtained after 162 
transfection of wild-type PC12 cells with the expression vectors, empty pCR3.1 or pCR3.1 163 
ERα containing the coding region cDNA of full length ERα. The stable transfections were 164 
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performed on PC12 cells, using the FuGENE6 reagent (Roche Diagnostics, Bâle, 165 
Switzerland). pCR3.1 plasmid also contains the resistance gene for geneticin antibiotics 166 
(G418, Invitrogen). The transfected cells, PC12 control clones (pCR3.1 empty) or PC12 ER 167 
(pCR3.1 ERα) clones were selected with 800 µg/ml of G418 for 1 month (Merot et al., 2005). 168 
The PC12 cells were then routinely cultured in phenol red-free DMEM/F12 medium (Sigma) 169 
containing 8% and 2% charcoal-stripped fetal calf and horse serum, respectively (FCS; 170 
Biowest and Life Technologies, Cergy Pontoise, France) with 400 µg/ml of G418 antibiotics 171 
treatment in order to keep stably transfected cell selection. The ERα expression was verified 172 
in the PC12 control and PC12 ER clones by western blot analysis (Fig. 3B). 173 
 174 
2.5. Determination of ERα -dependent proliferation of PC12 clones 175 
PC12 control clones and PC12 ERα clones were plated at 104 cells per well on 24-176 
wells plate in phenol red-free DMEM/F12 medium (Gibco, Life Technologies, Cergy 177 
Pontoise, France) containing 5% charcoal-stripped fetal calf (Biowest, Nuaille, France). 24 178 
hours later, ethanol or different concentrations of E2 were added. The medium was renewed 179 
every 2 days. The proliferation test was stopped at day 5 by trypsination and then 100 µl of 180 
fresh medium were added. Cells were then counted with malassez counting chamber. In order 181 
to verify our result and to assess the molecules effects a second proliferation test was 182 
performed. Cells were seeded onto 96-well plates at 2x10
3
 cells per well in phenol red-free 183 
DMEM/F12 containing 10% of serum (Horse and calf). Twenty-four hours later, cells were 184 
transferred into phenol red-free DMEM/F12 containing either 5% of charcoal stripped FCS 185 
(Sigma-Aldrich) for 24 hours. Then cells were treated with EtOH, E2 and others molecules 186 
for 7 days. The treatment was renewed every two days. At the end of the experiment, relative 187 
cell number was then assessed by quantification of cellular ATP content (ViaLight HS kit, 188 
Lonza). 189 
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 190 
2.6. Determination of ERα-dependent neurite outgrowth of PC12 cells 191 
PC12 control and PC12 ER clones, plated at a density of 4 x 10
4
 cells/well in 12-well 192 
plates, were transferred to phenol red-free DMEM/F12 medium containing 2 % charcoal-193 
stripped serum (1.6 % charcoal-stripped fetal calf serum and 0.4 % charcoal-stripped horse 194 
serum) and then treated with 5 ng/mL NGF and/or EtOH, E2, EE2, Gen, 4-OHT, Ral and 195 
BPA at different concentrations. Sixty hours later, the differentiation of PC12 cells was 196 
scored as previously described (Merot et al., 2005). Briefly, the cells with at least one neurite 197 
with a length greater than one cell body were scored on at least 30 fields (10 fields x 3 198 
separate experiments) under light microscopy. Results were expressed as the mean ratio of 199 
differentiating / total cells for each field. Secondly, the ratio adherents’ cells / total cells was 200 
also calculated for each experimental condition. 201 
 202 
2.7. Statistical analysis 203 
The statistical analyses were performed by an analysis of variance followed by 204 
analysis of individual group differences using the Statview 5.0 software (SAS Institute Inc., 205 
Cary, NC). One-way analysis of variance (ANOVA) was used to determine the effects of 206 
estrogenic compounds on transcription (for more details see figure 1) or on neuritogenesis 207 
(for more details, see figure 4). Moreover a two-way analysis (two-AOV) was used to 208 
determine possible interactions between 2 variables: 1) interaction between effects of NGF 209 
and effects of estrogenic compounds on transcription. 210 
 211 
3. RESULTS 212 
 213 
3.1. Transcriptional activity of EDCs in undifferentiated and differentiated PC12 cells 214 
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We evaluated the estrogenic activities of classical estrogenic compounds on the 215 
transcriptional activity through ERE and SP1 reporter assay in a context of undifferentiated or 216 
differentiated cells. In this way these activities were evaluated in PC12 cells treated or not 217 
with NGF. As expected, in the PC12 control cells (ER negative), the ERE-TK activity was not 218 
modified by either E2 or by the EDCs in the presence or in the absence of NGF treatment 219 
(Fig. 1A). By contrast, in the PC12 cells transiently transfected with ERα, the compounds E2, 220 
Gen, EE2 and BPA increased the ERE-TK transcriptional activity, whereas 4-OHT and Ral 221 
decreased it whatever the NGF status. Both of these effects occurred in a dose-dependent 222 
manner (Fig. 1B). In the ER negative cells, higher concentrations of BPA and 4-OHT slightly 223 
decreased the SP1-Luc activity (Fig. 2A). SP1 luciferase activity was regulated in ER 224 
dependent manner by the estrogenic compounds. Indeed, E2, Gen, EE2, 4-OHT and BPA 225 
upregulated the SP1 reporter gene transcriptional activity in the PC12 ER cells in the presence 226 
or not of NGF (Fig. 2B). No significant interaction was identified following a 2-way ANOVA 227 
analysis between the treatments with EDCs and NGF for both ERE- and SP1- dependent 228 
transcription. 229 
 230 
3.2. E2 and EDC promote a new selectivity on NGF-induced neurite outgrowth of PC12 ER 231 
clones 232 
The dose-related neuritogenic effects of estradiol or different EDCs were determined 233 
on PC12 cells that were stably transfected with either pCR3.1 ERαor the empty vector, 234 
pCR3.1. Treatment with NGF (5 ng/mL) for 60 h provoked the neurite outgrowth of PC12 235 
control and PC12 ER clones (Fig. 3A). The expression of ER in PC12 ER cells was confirmed 236 
by Western-Blot (Fig. 3B). 237 
E2 (10
-9
 and 10
-8
 M) significantly increased the NGF-inducedneurite extension of the 238 
PC12 ER clones but not the PC12control clones (Fig. 4A). Gen (concentrations from 10
-8
 to 239 
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10
-6
 M) and 4-OHT (concentrations from 10
-8
 to 10
-6
 M) also increased the NGF-240 
inducedneuritogenesis via an ERα-dependent mechanism (Fig. 4B-C). By contrast, EE2, Ral 241 
and BPA did not have significant effects on PC12 ER clones treated with NGF (Fig. 4D-F). In 242 
the absence of NGF, the compounds E2, EE2, Gen, 4-OHT, Ral and BPA did not modify 243 
neurite outgrowth of both PC12 ER and PC12 control clones (data not shown). Only the 244 
highest concentration of Gen (10
-5
 M) inhibited the neurite outgrowth in both the control and 245 
PC12 ER clones treated with NGF (Fig. 4B) and also decreased the ratio adherent cells / total 246 
cells (respectively 32 ± 8.5 % and 33.5 ± 12.5 % for PC12 ER and PC12 control clones, when 247 
this ratio was near 1 for other conditions (data not shown)).  248 
 249 
4. DISCUSSION  250 
Many studies reported that estrogens display neuroprotective effects (for review, see 251 
Habauzit et al, 2011) in physiopathological context of brain ischemia or Alzheimer’s disease. 252 
For instance E2 reduces in ER-dependent manner brain damage induced by cerebral occlusion 253 
(Dubal et al., 2001) or prevents hippocampal neurons (Miller et al., 2005) or PC12 cells 254 
(Ferriere et al., 2013) from apoptosis. Another target of estradiol in brain is neuronal 255 
extension (for review see Toran-Allerand et al., 1999). For instance, estradiol enhanced 256 
neurite proliferation in organotypic cultures of the newborn mouse forebrain (Toran-Allerand, 257 
1980) and in preoptic area grafted into adult rat brain(Matsumoto et al., 1988). In cell lineage, 258 
it was recently shown that E2 and diethylstilbestrol (DES) were able to increase the NGF 259 
induced neurite outgrowth in PC12 cells (Merot et al., 2005; Merot et al., 2009; Habauzit et 260 
al., 2011). But there are lacks in the evaluation of classical estrogenic compounds effect on 261 
cell differentiation and there is no available simple and fast cellular method for the estrogenic 262 
compounds differentiating effect evaluation other than those requiring animal testing. 263 
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Several in vitro assays have been developed to characterize the global and subcellular 264 
effects of EDCs (Andersen et al., 1999). Like E2, the effects of EDCs can be mediated by 265 
classical transcriptional mechanisms through ERs (Fujimoto et al., 2004), and a large number 266 
of in vitroshort-term tests were developed for this screening purpose. The majority of these 267 
tests were based on EDC-induced transcriptional activity in different cells, such as yeast (Petit 268 
et al., 1995) or mammalian cells, that were transiently transfected with reporter plasmids 269 
containing ERE (Andersen et al., 1999), SP1 or AP1 binding sites in their promoters (Safe, 270 
2001; Fujimoto et al., 2004; Schreihofer, 2005). These ER-dependent transcriptional effects 271 
had not yet been extensively studied in the context of pseudoneuronal PC12 cells, which can 272 
be present at undifferentiated or differentiated states. We found that E2, Gen, EE2 and BPA 273 
increase the ERE-dependent transcriptional activity of both undifferentiated and differentiated 274 
PC12 cells, whereas 4-OHT and Ral decreased this activity. These respective full agonistic 275 
and repressive effects were previously reported for other cell lines (Petit et al., 1995; 276 
Andersen et al., 1999; Paris et al., 2002; Fujimoto et al., 2004; Schreihofer, 2005). The 4-277 
OHT and Ral activity in PC12 cells may be dependent upon the cellular context of these cells 278 
and changes in the conformation of the ligand binding domain affecting the interaction of ER 279 
with coactivators or repressors (Smith and O'Malley, 2004). The ERE-mediated 280 
transcriptional effects of 4-OHT and Ral, which were observed in PC12 cells and MCF7 cells, 281 
were undetectable in neuro2A cells (Schreihofer, 2005). These differences underline the 282 
SERMs activities of these compounds. We clearly distinguish the activity of E2 from those of 283 
SERMs such as 4-OHT to modulate ERE-dependent genes/promoter construct. That was not 284 
true when we studied the ability of ER/ SP1 complexe to modulate transcription. Indeed, E2, 285 
4-OHT and BPA increased SP1-dependent transcriptional activity in PC12 cells transfected 286 
with ERα, as previously reported in breast cancer cells cotransfected with a SP1 construct and 287 
wild-type ERα(Kim et al., 2003; Safe and Kim, 2008; Wu et al., 2008).Gen, EE2 also 288 
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increased SP1-dependent transcription effects. Only Ral had no effects. Interestingly, profiles 289 
were similarin the context of undifferentiated or differentiated pseudoneuronal PC12 ER cells. 290 
The global effects of EDCs are demonstrated primarily by the proliferation of ER-291 
positive breast cancer cells, particularly MCF-7 (E-SCREEN) and T47D cell lines treated for 292 
4 to 6 days(Soto et al., 1992; Villalobos et al., 1995; Andersen et al., 1999; Fujimoto et al., 293 
2004; Habauzit et al., 2010). Indeed, if E2 effectively induces the proliferation of MCF7 and 294 
T47D cells at 10
-12 
M - 10
-9 
M, E2 had no effect on the proliferation of PC12 cells when it is 295 
tested in the same range of concentration in the present study (data not shown). Thus, the 296 
proliferation of PC12 cells cannot be considered as a valid model for the evaluation of the 297 
estrogenic effects of EDCs. 298 
Xeno-estrogens can also mediate differentiation processes either in vivo or in vitro in 299 
tissues such as the reproductive tract (Steinmetz et al., 1998; Svechnikov et al., 2010) or the 300 
brain (Panzica et al., 2009; Habauzit et al., 2011). These effects are not well documented. The 301 
global model of PC12 cell neuritogenesis can provide interesting specific information in the 302 
context of neuronal differentiation. A dose-dependent and ERα-dependent increase of the 303 
NGF-inducedneuritogenesis is observed in PC12 cells treated with E2. As previously reported 304 
(Gollapudi and Oblinger, 2001; Merot et al., 2005; Merot et al., 2009), E2 (10
-9
 and 10
-8
 M) 305 
significantly increased the NGF-inducedneurite extension of the PC12 ER clones but not the 306 
PC12control ones (Fig. 4A).We find that among the EDCs, Gen and 4-OHT also display 307 
estrogenic effects in PC12 ER clones in a concentration range of 10
-8 
M to10
-6
 M. By contrast, 308 
10
-5
 M Gen decreases neuritogenesis, as previously reported for high concentrations of this 309 
compound (Bouron et al., 1999). This inhibition appears to be ER-independent and could be 310 
explained by a toxic effect of Gen at this concentration. Indeed, we observed a decrease of 311 
more than 60% of adherent cells treated with 10
-5
 M Gen that could support this hypothesis. 312 
This effect has been already observed in rat primary cortical neurons (Linford et al., 2001). 313 
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The selective activation of ER by ligands that is dependent upon the tissue environment is 314 
true for the SERMs, 4-OHT and Ral. For instance, both Ral and 4-OHT displayed an anti-315 
estrogenic activity in a proliferation assay of T47D cells(Habauzit et al., 2010), whereas the 316 
ER could not discriminate among chemicals with estrogenic or anti-estrogenic activitiesin the 317 
context of yeast (Petit et al., 1995).In vivo, both Ral and 4-OHT displayed cell-specific 318 
estrogenic agonist activity in the skeleton and antagonist activity in the breast (Cauley et al., 319 
2001; Smith and O'Malley, 2004). However, Ral may lack the uterotrophic activity associated 320 
with tamoxifen (Delmas et al., 1997; Anthony et al., 2001). Like in the uterus, we found that 321 
Ral lacks in PC12 cells a neuritogenic activity compared with 4-OHT. However, Nilsen et al. 322 
demonstrated that Ral induced neurotrophic effects in PC12 ER positive cells (Nilsen et al., 323 
1998). The opposite results could be explained by the experimental procedures and by the 324 
levels of ERα expressed in those cells. Indeed, Nilsen et al. induced ERα expression with a 2-325 
week NGF treatment, whereas we used the stable transfection of PC12 cells. BPA and EE2 326 
are generally defined as estrogenic compounds. Concentration of BPA was found in several 327 
biological samples such as blood, milk and urine (Lee et al., 2013). BPA mimics E2 in 328 
numerous in vivo and in vitro studies in a concentration range of 10
-9 
M to 10
-5 
M. For 329 
example, BPA induced cell proliferation in the uterus of ovariectomized rats in vivo,and its 330 
effects were nearly identical to those induced by E2 (Steinmetz et al., 1998). BPA did not 331 
modify neuritogenesis of PC12 ER clones, even at the highest concentrations used (10
-7 
M 332 
and 10
-6
 M), whereas E2 and the well-established estrogenic compound diethylstilbestrol 333 
increased neuritogenesis at a concentration of 10
-9
 M (Merot et al., 2009). In PC12 cells, only 334 
concentrations of BPA higher than 50 μM had been reported to decrease viability and neurite 335 
extension via an ER-dependent mechanism(Lee et al., 2007). EE2 is a clinically relevant 336 
estrogenic compound that is more potent than E2 and is widely used for birth control (Lobo 337 
and Stanczyk, 1994). With regard to the subcellular or global cellular assays of estrogenicity, 338 
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10
-10 
M to 10
-9 
M EE2 can display strong estrogenic activity. It is verified using the ERE-339 
dependent transcriptional activity in PC12 cells (present study) or in the global model of 340 
proliferation in T47D or MCF7 cells (Andersen et al., 1999; Habauzit et al., 2010). By 341 
contrast, EE2 did not modify PC12 neuritogenesis in the concentration range of 10
-10 
M to 10
-
342 
7 
M. Distinct biological cell-specific potencies of E2 and EE2 that are mediated by the ER are 343 
not usually reported. However, E2, but not EE2, induced ER-dependent NO synthesis and 344 
protection against oxidative stress in endothelial cell cultures (Andozia et al., 2010). 345 
The effects of EDCs on ERE-, SP1-mediated transcription in undifferentiated and 346 
differentiated PC12 cells gave profiles that have been classically reported for other cell lines, 347 
especially for breast cancer cells. The global analysis of neuritogenesis in PC12 cells stably 348 
transfected with ERα has demonstrated a selectivity of the EDCs that is distinct from that 349 
observed for the subcellular bioassay of transcription. The effects of estrogens can be the 350 
result in neuronal cells of a tissue-specific complex interplay of the activation/inhibition of 351 
DNA binding-dependent, DNA binding-independent gene transcription but also membrane-352 
initiated mechanisms (Habauzit et al. 2011). The pathways involved in the EDC-induced 353 
neuritogenesis in the PC12 ER clones could be different from those involved in the 354 
differentiation and proliferation of other cell lines and could be linked to the specific cellular 355 
context, especially the presence of specific transcription factors, coactivators and corepressors 356 
(Smith and O'Malley, 2004). 357 
In the future, investigations into the mechanisms that sustain the effects of EDCs 358 
should integrate different approaches and interassay comparisons. As a result, the 359 
determination of neurite outgrowth of PC12 ER clones constitutes an original and 360 
complementary global bioassay for the characterization of xeno-estrogens. PC12 ER clones 361 
and cells expressing different deleted or mutated forms of ERα have been previously used to 362 
investigate subcellular ER-dependent mechanisms sustaining E2 activity (Merot et al., 2009). 363 
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Thus, neuritogenic effects of E2 were suppressed in PC12 cells stably transfected with a DNA 364 
binding domain deleted ERα (Merot et al., 2009). These different PC12 clones could also be 365 
used to characterize the ER domains that are involved in the effects of EDCs. Moreover, these 366 
PC12 clones provide the basis for further studies focusing on the effects of EDCs in the 367 
specific context of brain development or diseases, which remain poorly documented.  368 
 369 
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Figure Legends  562 
 563 
Fig. 1. The transcriptional effects of estrogenic compounds measured by the ERE-TK-Luc 564 
reporter assay in undifferentiated or differentiated PC12 cells. PC12 cells were transiently 565 
transfected with ERE-TK-Luc reporter gene together with CMV-β-Gal and the empty pCR3.1 566 
plasmid (A) or the pCR3.1 plasmid encoding ERα (B). Twelve hours after transfection, the 567 
cells were differentiated or not with NGF (5 ng/mL) (respectively right and left panels) and 568 
treated with vehicle control ethanol (EtOH) or 17 β estradiol (E2: 10-9 M), genistein (Gen: 10-569 
9
 M and 10
-7
 M), 17 α ethynylestradiol (EE2: 10-9 M and 10-7 M), 4-hydroxytamoxifen (4-570 
OHT: 10
-9 
M and 10
-6
 M), raloxifen (Ral: 10
-7
 M), bisphenol A (BPA: 10
-9
 M and 10
-7
 M) for 571 
30 h. The luciferase activities after E2 and EDCs treatments were expressed in reference (fold 572 
induction) to the luciferase activity measured in cells treated with EtOH (A and B). The data 573 
are the mean ± SEM of four experiments. No significant interaction was identified following a 574 
2-way ANOVA analysis of the EDC and NGF treatments. *, P < 0.05; **, P < 0.01 and ***, 575 
P < 0.001: for the significant effects of the estrogenic compounds compared to the respective 576 
controls, which are the cells treated with EtOH +/- NGF. 577 
 578 
Fig. 2. The transcriptional effects of estrogenic compounds measured by the SP1-luc reporter 579 
assay in undifferentiated or differentiated PC12 cells. PC12 cells were transiently transfected 580 
with SP1-Luc reporter gene together with CMV-β-Gal and the empty pCR3.1 plasmid (A) or 581 
the pCR3.1 plasmid encoding ERα (B). Cells were then differentiated or not with NGF and 582 
treated with control EtOH or E2, Gen, EE2, 4-OHT, Ral, BPA for 30 h (for more details, see 583 
Figure 1).  584 
 585 
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Fig. 3. PC12 clones obtained after stable transfection. (A) PC12 cells stably transfected with 586 
pCR3.1 plasmid encoding ERα (PC12 ER clones) or the empty pCR3.1 plasmid (PC12 587 
Control clones). The NGF treatment induces neurite outgrowth of both PC12 clones (lower 588 
panel). (B) ERα expression was controlled by western blot in PC12 clones that stably express 589 
ERα (PC12 ER) or that do not express ERα (PC12 control), and the expression of β-Actin was 590 
used as internal control.  591 
 592 
Fig. 4. Neuritogenic effects of estrogenic compounds in PC12 clones. Neurite outgrowth was 593 
induced by treatment with NGF (5 ng/ml) for 2 days in the PC12 clones that stably express 594 
ERα (PC12 ER) or not (PC12 control). Simultaneously with NGF, clones were treated with 595 
different concentrations of 17 β estradiol (A) and EDCs (B-F). The neurite outgrowth was 596 
quantified by scoring the ratio differentiated cells/undifferentiated cells for each microscopy 597 
field. Differentiated cells were ones that have at least one neurite that the length is greater 598 
than one cell body. For both PC12 control and PC12 ER clones, results were expressed in 599 
reference (fold induction) to the neurite outgrowth of differentiated cells treated with EtOH. *, 600 
P < 0.05; **, P < 0.01 and ***, P < 0.001: significant effects of the different concentrations 601 
of EDCs in reference with EtOH. The data are the mean ± SEM of 30 to110 light microscopy 602 
fields. 603 
604 
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